Latest Commercial Milestones News

Cardiex Limited has formally lodged its CONNEQT Pulse device with Australia's Therapeutics Goods Administration, marking a critical step toward regulatory approval and market expansion.

Dimerix has received a US$30 million upfront payment from Amicus Therapeutics for exclusive US rights to DMX-200, a promising kidney disease therapy. The deal positions Dimerix for up to US$560 million in further milestones plus royalties, underpinning its global licensing strategy.

Bio-Gene Technology Limited is progressing its development of two novel insecticidal compounds, Qcide and Flavocide, targeting major global markets with strong commercial validation and significant US Department of Defense funding.

ClearVue Technologies has secured its first commercial rooftop contract in Sydney’s CBD, supplying innovative solar glass for the City Tattersalls Club redevelopment to boost sustainability and energy efficiency.

Nanoveu Limited has successfully raised $2.3 million through a share placement to accelerate development and commercialization of its cutting-edge semiconductor, 3D visualization, and solar coating technologies.

Anatara Lifesciences has obtained a $400,000 loan advance from a major shareholder group against its estimated R&D tax refund for the first half of FY2025, providing crucial funding to support ongoing clinical trials and product development without immediate capital raising.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.

1414 Degrees Ltd advances its transformation into a full-service decarbonised energy provider, delivering key technology and commercial milestones in Q3 FY25 while maintaining a stable cash position.

Dimerix Limited advances its Phase 3 kidney disease trial with FDA acceptance of proteinuria as a primary endpoint and clinches a lucrative licensing agreement in Japan worth up to AU$107 million plus royalties.

Zoono Group Limited reports strong progress in its shelf-life extension technology trials across multiple continents, with successful UK supermarket trials paving the way for a national roll-out in FY26. Despite a quarterly operating cash outflow, the company expects improved sales and sufficient funding to meet its near-term objectives.

Wide Open Agriculture has inked an exclusive 18-month distribution agreement with Univar Solutions China to market its lupin protein products, marking a strategic push into the lucrative Chinese plant-based protein sector.

Imugene Limited reports encouraging Phase 1b results for azer-cel in lymphoma, secures FDA Fast Track status, and strengthens patent portfolio while raising A$20 million to fuel ongoing immuno-oncology programs.